J&J ex­pands Trem­fya in­to IBD with new FDA ap­proval

The FDA has ap­proved John­son & John­son’s IL-23 block­er Trem­fya to treat ul­cer­a­tive col­i­tis, a boost to the phar­ma’s hopes that the drug will serve …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA